Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Robyn Thorington und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea, Ceftriaxone, Anti-Bacterial Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Public Health Agency of Canada.
Abstract (Originalsprache)
Objective
From 2017 to 2024, there were 16 cases of ceftriaxone-resistant gonorrhoea in Canada, 8 of which were isolated in 2024, including one XDR case. We describe the clinical and demographic details of all 16 cases and examine the phenotypic and molecular characteristics of each case. To investigate the relatedness of the cases both to each other and to international isolates, a phylogenetic tree was constructed.
Methods
All 16 ceftriaxone-resistant isolates underwent WGS and were compared to the international isolates. Antimicrobial susceptibility testing was completed by agar dilution following the CLSI protocol.
Results
Ceftriaxone MICs for the 16 isolates range between 0.25 and 2 mg/L. All cases were isolated from genital sites, and four cases were probable treatment failures. Ten of the cases were linked to international travel. Seven of the isolates were part of the NG-STAR ST 233 clonal complex. All 16 cases have penA alleles associated with cephalosporin resistance, including penA 60.001, penA 121.002, penA 237.001 and penA 294.002.
Conclusion
We summarize 16 cases of ceftriaxone-resistant gonorrhoea that were isolated in Canada from 2017 to 2024. We determined the penA allele type for each case and detected molecular markers associated with cephalosporin resistance. Local public health investigations and the genomic data for each case indicate that the strains did not spread further in the population. To date, ceftriaxone remains an effective treatment for gonorrhoea, but continued surveillance is required to ensure detection and thus prevent the further spread of ceftriaxone-resistant Neisseria gonorrhoeae in Canada.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
- Centre for Communicable Diseases and Infection Control Branch, Public Health Agency of Canada, Ottawa, Ontario, Canada.
- Public Health Ontario Laboratory, Toronto, Ontario, Canada.
- Bacteriology, BC Centre for Disease Control Public Health Laboratory, Vancouver, British Columbia, Canada.
- Laboratoire de Santé Publique du Québec, Ste-Anne-de-Bellevue, Québec, Canada.
- Alberta Precision Laboratories, Provincial Laboratory for Public Health, Edmonton, Alberta, Canada.
ORCID-Profile: Robyn Thorington, Shelley W Peterson
Förderung
- Public Health Agency of Canada
Zitieren
APA
Thorington, R., Barairo, N., Peterson, S. W., Lourenço, L., Tran, V., Grant, J., Lefebvre, B., Dingle, T. C., Gravel, G., & Martin, I. (2026). Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag007
Vancouver
Thorington R, Barairo N, Peterson SW, Lourenço L, Tran V, Grant J, et al. Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag007
BibTeX
@article{Thorington2026,
author = {Thorington, Robyn and Barairo, Norman and Peterson, Shelley W and Lourenço, Lillian and Tran, Vanessa and Grant, Jennifer and Lefebvre, Brigitte and Dingle, Tanis C and Gravel, Geneviève and Martin, Irene},
title = {Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag007}
}
EUVIMED